FDA.reportPublic FDA data

PALBOCICLIB Pharmacologic Class Indexing

Class set ID
aba073bf-ca15-4441-b95e-08caf82a34e9
Version
2
Effective date
20180813
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use IBRANCE safely and effectively. See full prescribing information for IBRANCE. IBRANCE ® (palbociclib) tablets, for oral use Initial U.S. Approval: 2015U.S. Pharmaceuticals | Viatris Pharmaceuticals LLC | Pfizer Ireland Pharmaceuticals Unlimited Company | Pfizer Manufacturing Deutschland GmbH2026053010
These highlights do not include all the information needed to use IBRANCE safely and effectively. See full prescribing information for IBRANCE. IBRANCE ® (palbociclib) capsules, for oral use Initial U.S. Approval: 2015Pfizer Laboratories Div Pfizer Inc | Pharmacia & Upjohn Company LLC | Pfizer Ireland Pharmaceuticals Unlimited Company | Pfizer Manufacturing Deutschland GmbH | Pfizer Asia Manufacturing Pte Ltd2026022521
These highlights do not include all the information needed to use IBRANCE safely and effectively. See full prescribing information for IBRANCE. IBRANCE ® (palbociclib) tablets, for oral use Initial U.S. Approval: 2015Pfizer Laboratories Div Pfizer Inc | Pfizer Ireland Pharmaceuticals Unlimited Company | Pfizer Manufacturing Deutschland GmbH | Pfizer Asia Manufacturing Pte Ltd2026022512